David A. Siegel Aerovate Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 7,800 shares of AVTE stock, worth $12,636. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,800Holding current value
$12,636% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVTE
# of Institutions
81Shares Held
20.3MCall Options Held
0Put Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$6.09 Million6.47% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.2MShares$3.57 Million6.85% of portfolio
-
Atlas Venture Life Science Advisors, LLC2.04MShares$3.3 Million7.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.68MShares$2.72 Million0.63% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.2MShares$1.95 Million1.87% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $39.6M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...